bdtx-4933

BDTX-4933 is a central nervous system (CNS)-penetrant small molecule inhibitor targeting the serine/threonine protein kinase Raf family, with potential antineoplastic activity. It is designed to inhibit both RAF and RAS pathway alterations in solid tumors. The drug was originally developed by Black Diamond Therapeutics and later licensed globally to Servier for further development and commercialization. BDTX-4933 is being investigated as a targeted therapy for patients with cancers harboring KRAS (non-G12C), BRAF, CRAF (RAF1), or NRAS mutations—particularly in advanced/metastatic non-small cell lung cancer (NSCLC), melanoma, histiocytic neoplasms, and other solid tumors with relevant mutations. Its oral formulation allows self-administration in clinical trials[1][2][4][5][6].